Gadolinium deposition in the brain: current knowledge and recommendations
Abstract
Gadolinium based contrast agents (GBCAs) have been widely used intravenously in MRI examinations and are considered relatively safe in patients with intact renal function. However, since 2014, repeated administrations of GBCAs have been associated to high MRI signal intensity in deep brain nuclei, on unenhanced T1-weighted images, a finding that has been attributed to gadolinium (Gd) parenchymal deposition. Deep brain nuclei Gd deposition is variable among different agents available for clinical practice and is considered greater with linear GBCAs compared to macrocyclic agents. The clinical significance of Gd brain retention has not been extensively studied and remains, to a great extent, undetermined. In this review article, the biochemical structure of GBCAs, the clinical and pathologic studies investigating morphological and histological changes after multiple intravenous Gd administration, the suggested pathogenetic mechanisms and the recent recommendations towards safe use of these agents are summarised.
Keywords
Full Text:
PDFReferences
Runge VM, Carollo BR, Wolf CR, et al. Gd DTPA: a review of clinical indications in central nervous system magnetic resonance imaging. Radiographics 1989; 9(5): 929-958.
Gulani V, Calamante F, Shellock FG, et al. Gadolinium deposition in the brain: summary of evidence and recommendations. Lancet Neurol 2017; 16(7): 564-570.
Marckmann P, Skov L, Rossen K, et al. Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol 2006; 17(9): 2359-2362.
Daftari Besheli L, Aran S, Shaqdan K, et al. Current status of nephrogenic systemic fibrosis. Clin Radiol 2014; 69(7): 661-668.
Kanda T, Ishii K, Kawaguchi H, et al. High signal intensity in the dentate nucleus and globus pallidus on unenhanced T1-weighted MR images: relationship with increasing cumulative dose of a gadolinium-based contrast material. Radiology 2014; 270(3): 834-841.
Errante Y, Cirimele V, Mallio CA, et al. Progressive increase of T1 signal intensity of the dentate nucleus on unenhanced magnetic resonance images is associated with cumulative doses of intravenously administered gadodiamide in patients with normal renal function, suggesting dechelation. Invest Radiol 2014; 49: 685-690.
Radbruch A, Weberling LD, Kieslich PJ, et al. Gadolinium retention in the dentate nucleus and globus pallidus is dependent on the class of contrast agent. Radiology 2015; 275(3): 783-791.
Ramalho J, Castillo M, AlObaidy M, et al. High signal intensity in globus pallidus and dentate nucleus on unenhanced T1-weighted MR images: evaluation of two linear gadolinium-based contrast agents. Radiology 2015; 276(3): 836-844.
Quattrocchi CC, Mallio CA, Errante Y, et al. Gadodiamide and dentate nucleus T1 hyperintensity in patients with meningioma evaluated by multiple follow-up contrast-enhanced magnetic resonance examinations with no systemic interval therapy. Invest Radiol 2015; 50(7): 470-472.
Weberling LD, Kieslich PJ, Kickingereder P, et al. Increased signal intensity in the dentate nucleus on unenhanced T1-weighted images after gadobenate dimeglumine administration. Invest Radiol 2015; 50(11): 743-748.
Adin ME, Kleinberg L, Vaidya D, et al. Hyperintense dentate nuclei on T1-weighted MRI: Relation to repeat gadolinium administration. Am J Neuroradiol 2015; 36(10): 1859-1865.
Kanda T, Osawa M, Oba H, et al. High signal intensity in dentate nucleus on unenhanced T1-weighted mr images: association with linear versus macrocyclic gadolinium chelate administration. Radiology 2015; 275(3): 803-809.
Radbruch A, Weberling LD, Kieslich PJ, et al. Gadolinium retention in the dentate nucleus and globus pallidus is dependent on the class of contrast agent. Radiology 2015; 275(3): 783-791.
Ramalho J, Semelka RC, AlObaidy M, et al. Signal intensity change on unenhanced T1-weighted images in dentate nucleus following gadobenate dimeglumine in patients with and without previous multiple administrations of gadodiamide. Eur Radiol 2016; 26(11): 4080-4088.
Tedeschi E, Palma G, Canna A, et al. In vivo dentate nucleus MRI relaxometry correlates with previous administration of Gadolinium-based contrast agents. Eur Radiol 2016; 26(12): 4577-4584.
Radbruch A, Weberling LD, Kieslich PJ, et al. Intraindividual analysis of signal intensity changes in the dentate nucleus after consecutive serial applications of linear and macrocyclic gadolinium-based contrast agents. Invest Radiol 2016; 51(11): 683-690.
Stojanov DA, Aracki-Trenkic A, Vojinovic S, et al. Increasing signal intensity within the dentate nucleus and globus pallidus on unenhanced T1W magnetic resonance images in patients with relapsing-remitting multiple sclerosis: correlation with cumulative dose of a macrocyclic gadolinium-based contrast age. Eur Radiol 2016; 26(3): 807-815.
Bjørnerud A, Vatnehol SAS, Larsson C, et al. Signal enhancement of the dentate nucleus at unenhanced MR imaging after very high cumulative doses of the macrocyclic gadolinium-based contrast agent gadobutrol: an observational study. Radiology 2017; 285(2): 434-444.
Zhang Y, Cao Y, Shih GL, et al. Extent of signal hyperintensity on unenhanced T1-weighted Brain MR images after more than 35 administrations of linear gadolinium-based contrast agents. Radiology 2017; 282(2): 516-525.
Khant ZA, Hirai T, Kadota Y, et al. Shortening in the cerebral cortex after multiple administrations of gadolinium-based contrast agents. Magn Reson Med Sci 2017; 16(1): 84-86.
Kuno H, Jara H, Buch K, et al. Global and regional brain assessment with quantitative MR imaging in patients with prior exposure to linear gadolinium-based contrast agents. Radiology 2017; 283(1): 195-204.
Conte G, Preda L, Cocorocchio E, et al. Signal intensity change on unenhanced T1-weighted images in dentate nucleus and globus pallidus after multiple administrations of gadoxetate disodium: an intraindividual comparative study. Eur Radiol 2017; 27(10): 4372-4378.
Radbruch A, Haase R, Kickingereder P, et al. Pediatric Brain: no increased signal intensity in the dentate nucleus on unenhanced T1-weighted MR images after consecutive exposure to a macrocyclic gadolinium-based contrast agent. Radiology 2017; 283(3): 828-836.
Tedeschi E, Cocozza S, Borrelli P, et al. Longitudinal assessment of dentate nuclei relaxometry during massive gadobutrol exposure. Magn Reson Med Sci 2018; 17(1): 100-104.
Moser FG, Watterson CT, Weiss S, et al. High signal intensity in the dentate nucleus and globus pallidus on unenhanced T1-weighted MR images: Comparison between gadobutrol and linear gadolinium-based contrast agents. AJNR Am J Neuroradiol 2018; 39(3): 421-426.
Eisele P, Alonso A, Szabo K, et al. Lack of increased signal intensity in the dentate nucleus after repeated administration of a macrocyclic contrast agent in multiple sclerosis. An observational study. Medicine (Baltimore) 2016; 95(39): e4624.
Miller JH, Hu HH, Pokorney A, et al. MRI brain signal intensity changes of a child during the course of 35 gadolinium contrast examinations. Pediatrics 2015; 136(6): e1637-1640.
Roberts DR, Holden KR. Progressive increase of T1 signal intensity in the dentate nucleus and globus pallidus on unenhanced T1-weighted MR images in the pediatric brain exposed to multiple doses of gadolinium contrast. Brain Dev 2016; 38(3): 331-336.
Hu HH, Pokorney A, Towbin RB, et al. Increased signal intensities in the dentate nucleus and globus pallidus on unenhanced T1-weighted images: evidence in children undergoing multiple gadolinium MRI exams. Pediatr Radiol 2016; 46(11): 1590-1598.
Roberts DR, Chatterjee AR, Yazdani M, et al. Pediatric patients demonstrate progressive T1 weighted hyperintensity in the dentate nucleus following multiple doses of gadolinium-based contrast agent. AJNR Am J Neuroradiol 2016; 37(12): 2340-2347.
Flood TF, Stence NV, Maloney JA, et al. Pediatric brain: repeated exposure to linear gadolinium-based contrast material is associated with increased signal intensity at unenhanced T1-weighted MR imaging. Radiology 2017; 282(1): 222-228.
Tibussek D, Rademacher C, Caspers J, et al. Gadolinium brain deposition after macrocyclic gadolinium administration: a pediatric case-control study. Radiology 2017; 285(1): 223-230.
Rossi Espagnet MC, Bernardi B, Pasquini L, et al. Signal intensity at unenhanced T1-weighted magnetic resonance in the globus pallidus and dentate nucleus after serial administrations of a macrocyclic gadolinium-based contrast agent in children. Pediatr Radiol 2017; 47(10): 1345-1352.
Lancelot E, Raynaud JS, Desché P. Lack of evidence of a relationship between magnetic resonance signal intensity changes in the globus pallidus and dentate nucleus, and repeated administrations of gadoterate meglumine in children. Pediatr Radiol 2017; 47(12): 1692-1693.
Schneider GK, Stroeder J, Roditi G, et al. T1 signal measurements in pediatric brain: Findings after multiple exposures to gadobenate dimeglumine for imaging of nonneurologic disease. AJNR Am J Neuroradiol 2017; 38(9): 1799-1806.
Renz DM, Kümpel S, Böttcher J, et al. Comparison of unenhanced T1-weighted signal intensities within the dentate nucleus and the globus pallidus after serial applications of gadopentetate dimeglumine versus gadobutrol in a pediatric population. Invest Radiol 2018; 53(2): 119-127.
Ryu YJ, Choi YH, Cheon JE, et al. Pediatric brain: gadolinium deposition in dentate nucleus and globus pallidus on unenhanced T1-weighted images is dependent on the type of contrast agent. Invest Radiol 2018; 53(4): 246-255.
Young JR, Orosz I, Franke MA, et al. Gadolinium deposition in the paediatric brain: T1-weighted hyperintensity within the dentate nucleus following repeated gadolinium-based contrast agent administration. Clin Radiol 2018; 73(3): 290-295.
Robert P, Lehericy S, Grand S, et al. T1-weighted hypersignal in the deep cerebellar nuclei after repeated administrations of gadolinium-based contrast agents in healthy rats: difference between linear and macrocyclic agents. Invest Radiol 2015; 50(8): 473-480.
Jost G, Lenhard DC, Sieber MA, et al. Signal increase on unenhanced T1-weighted images in the rat brain after repeated, extended doses of gadolinium-based contrast agents comparison of linear and macrocyclic agents. Invest Radiol 2016; 51(2): 83-89.
Robert P, Violas X, Grand S, et al. Linear gadolinium-based contrast agents are associated with brain gadolinium retention in healthy rats. Invest Radiol 2016; 51(2): 73-82.
Kartamihardja AAP, Nakajima T, Kameo S, et al. Distribution and clearance of retained gadolinium in the brain: Differences between linear and macrocyclic gadolinium based contrast agents in a mouse model. Br J Radiol 2016; 89(1066): 20160509.
Lohrke J, Frisk AL, Frenzel T, et al. Histology and gadolinium distribution in the rodent brain after the administration of cumulative high doses of linear and macrocyclic gadolinium-based contrast agents. Invest Radiol 2017; 52(6): 324-333.
Smith APL, Marino M, Roberts J, et al. Clearance of gadolinium from the brain with no pathologic effect after repeated administration of gadodiamide in healthy rats: an analytical and histologic study. Radiology 2017; 282(3): 743-751.
McDonald RJ, McDonald JS, Dai D, et al. Comparison of gadolinium concentrations within multiple rat organs after intravenous administration of linear versus macrocyclic gadolinium chelates. Radiology 2017; 285(2): 536-545.
Boyken, J, Frenzel T, Lohrke J, et al. Gadolinium accumulation in the deep cerebellar nuclei and globus pallidus after exposure to linear but not macrocyclic gadolinium-based contrast agents in a retrospective pig study with high similarity to clinical conditions. Invest Radiol 2018; 53(5): 278-285.
Rasschaert M, Emerit A, Fretellier N, et al. Gadolinium retention, brain T1 hyperintensity, and endogenous metals: a comparative study of macrocyclic versus linear gadolinium chelates in renally sensitized rats. Invest Radiol 2018; 53(6): 328-337.
McDonald RJ, McDonald JS, Kallmes DF, et al. Intracranial gadolinium deposition after contrast-enhanced MR imaging. Radiology 2015; 275(3): 772-782.
Kanda T, Fukusato T, Matsuda M, et al. Gadolinium-based contrast agent accumulates in the brain even in subjects without severe renal dysfunction: evaluation of autopsy brain specimens with inductively coupled plasma mass spectroscopy. Radiology 2015; 276: 228-232.
Murata N, Gonzalez-Cuyar LF, Murata K, et al. Macrocyclic and other non-group 1 gadolinium contrast agents deposit low levels of gadolinium in brain and bone tissue: Preliminary results from 9 patients with normal renal function. Invest Radiol 2016; 51(7): 447-453.
McDonald RJ, McDonald JS, Kallmes DF, et al. Gadolinium deposition in human brain tissues after contrast-enhanced MR imaging in adult patients without intracranial abnormalities. Radiology 2017; 285(2): 546-554.
Rogosnitzky M and Branch S. Gadolinium-based contrast agent toxicity: a review of known and proposed mechanisms. Biometals 2016; 29: 365-376.
Frenzel T, Lengsfeld P, Schirmer H, et al. Stability of gadolinium-based magnetic resonance imaging contrast agents in human serum at 37 degrees C. Invest Radiol 2008; 43(12): 817-828.
Dekkers IA, Roos, R, Van AD. Gadolinium retention after administration of contrast agents based on linear chelators and the recommendations of the european medicines agency. Eur Radiol 2017; 28: 1579-1584.
Port M, Idée J-M, Medina C, et al. Efficiency, thermodynamic and kinetic stability of marketed gadolinium chelates and their possible clinical consequences: a critical review. BioMetals 2008; 21(4): 469-490.
Olchowy C, Cebulski K, Łasecki M, et al. The presence of the gadolinium-based contrast agent depositions in the brain and symptoms of gadolinium neurotoxicity-A systematic review. PLoS One 2017; 12(2): 1-14.
Splendiani A, Perri M, Marsecano C, et al. Effects of serial macrocyclic-based contrast materials gadoterate meglumine and gadobutrol administrations on gadolinium-related dentate nuclei signal increases in unenhanced T1-weighted brain: a retrospective study in 158 multiple sclerosis (MS) patients. Radiol Medica 2018; 123(2): 125-134.
Update on FDA approach to safety issue of gadolinium retention after administration of gadolinium-based contrast agents. https://www.fda.gov/Drugs/DrugSafety/ucm589213.htm. Accessed March 3, 2019.
Engelhardt B, Sorokin L. The blood-brain and the blood-cerebrospinal fluid barriers: Function and dysfunction. Semin Immunopathol 2009; 31(4): 497-511.
Taoka T, Naganawa S. Gadolinium-based contrast media, cerebrospinal fluid and the glymphatic system: possible mechanisms for the deposition of gadolinium in the brain. Magn Reson Med Sci 2018; 17(2): 111-119.
Öner AY, Barutcu B, Aykol S, et al. Intrathecal contrast-enhanced magnetic resonance imaging-related brain signal changes: residual gadolinium deposition? Invest Radiol 2017; 52(4): 195-197.
Popescu BFG, Robinson CA, Rajput A, et al. Iron, copper, and zinc distribution of the cerebellum. Cerebellum 2009; 8(2): 74-79.
Tedeschi E, Caranci F, Giordano F, et al. Gadolinium retention in the body: what we know and what we can do. Radiol Medica 2017; 122(8): 589-600.
McDonald RJ, Levine D, Weinreb J, et al. Gadolinium retention: a research roadmap from the 2018 NIH/ACR/RSNA workshop on gadolinium chelates. Radiology 2018; 289(2): 517-534.
Prince MR, Zhang H, Zou Z, et al. Incidence of immediate gadolinium contrast media reactions. AJR Am J Roentgenol 2011; 196(2): 138-143.
Burke LMB, Ramalho M, AlObaidy M, et al. Self-reported gadolinium toxicity: A survey of patients with chronic symptoms. Magn Reson Imaging 2016; 34(8): 1078-1080.
Welk B, McArthur E, Morrow SA, et al. Association between gadolinium contrast exposure and the risk of parkinsonism. JAMA 2016; 316(1): 96-98.
Perrotta G, Metens T, Absil J, et al. Absence of clinical cerebellar syndrome after serial injections of more than 20 doses of gadoterate, a macrocyclic GBCA: a monocenter retrospective study. J Neurol 2017; 264(11): 2277-2283.
Bussi S, Coppo A, Botteron C, et al. Differences in gadolinium retention after repeated injections of macrocyclic MR contrast agents to rats. J Magn Reson Imaging 2018; 47(3): 746-752.
Roccatagliata L, Vuolo L, Bonzano L, et al. Multiple sclerosis: hyperintense dentate nucleus on unenhanced T1-weighted MR images is associated with the secondary progressive subtype. Radiology 2009; 251(2): 503-510.
Agris J, Pietsch H, Balzer T. What evidence is there that gadobutrol causes increasing signal intensity within the dentate nucleus and globus pallidus on unenhanced T1W MRI in patients with RRMS? Eur Radiol 2016; 26: 816-817.
Schlemm L, Chien C, Bellmann-Strobl J, et al. Gadopentetate but not gadobutrol accumulates in the dentate nucleus of multiple sclerosis patients. Mult Scler J 2017; 23(7): 963-972.
Suzuki S, Nishio S, Takata K, et al. Radiation-induced brain calcification: Paradoxical high signal intensity in T1-weighted MR images. Acta Neurochir (Wien) 2000; 142(7): 801-804.
Tamrazi B, Nguyen B, Liu C-SJ, et al. Changes in Signal intensity of the dentate nucleus and globus pallidus in pediatric patients: impact of brain irradiation and presence of primary brain tumors independent of linear gadolinium-based contrast agent administration. Radiology 2018; 287(2): 452-460.
Lim WH, Choi SH, Yoo RE, et al. Does radiation therapy increase gadolinium accumulation in the brain? Quantitative analysis of T1 shortening using R1 relaxometry in glioblastoma multiforme patients. PLoS One 2018; 13(2): e 0192838.
Aime S, Caravan P. Biodistribution of gadolinium-based contrast agents, including gadolinium deposition. J Magn Reson Imaging 2009; 30(6): 1259-1267.
Rahatli FK, Donmez FY, Kibaroglu S, et al. Does renal function affect gadolinium deposition in the brain? Eur J Radiol 2018; 104: 33-37.
U.S. Food and Drug Administration. (2017). FDA Warns that Gadolinium based contrast agents (gbcas) are retained in the body; Requires new class warnings. https://www.fda.gov/downloads/Drugs/DrugSafety/ UCM589442. Accessed March 3 2019.
European Medicines Agency (2017). EMA’s final opinion confirms restrictions on use of linear gadolinium agents in body scans. http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2017/ 07/WC500231829.pdf. Accessed October 23 2018.
Vergauwen E, Vanbinst AM, Brussaard C, et al. Central nervous system gadolinium accumulation in patients undergoing periodical contrast MRI screening for hereditary tumor syndromes. Hered Cancer Clin Pract 2018; 16(1): 2.
DOI: http://dx.doi.org/10.36162/hjr.v4i2.273
Refbacks
- There are currently no refbacks.